Open AccessmiR-216a-5p acts as an oncogene in renal cell carcinoma
Author(s) -
Peijie Chen,
Jing Quan,
Lü Jin,
Canbin Lin,
Weijie Xu,
Jinling Xu,
Xin Guan,
Zebo Chen,
Liangchao Ni,
Shangqi Yang,
Yun Chen,
Yongqing Lai
Publication year - 2018
Publication title -
experimental and therapeutic medicine
Language(s) - English
Resource type - Journals
eISSN - 1792-1015
pISSN - 1792-0981
DOI - 10.3892/etm.2018.5881
Subject(s) - oncogene , molecular medicine , cell cycle , cancer research , apoptosis , viability assay , renal cell carcinoma , cell growth , cell , downregulation and upregulation , motility , biology , cancer , chemistry , medicine , microbiology and biotechnology , gene , biochemistry
MiR-216a-5p has been acknowledged as an oncogene and is known to be involved in the progression and metastasis of numerous cancer subtypes. However, the potential role of miR-216a-5p in renal cell carcinoma (RCC) remains to be elucidated. In the present study, reverse transcription-quantitative polymerase chain reaction was performed to detect the expression levels of miR-216a-5p in RCC tissues. Cell counting kit-8, MTT, wound scratch, Transwell and flow cytometric assays were performed to establish the biological functions of miR-216a-5p in RCC. Functional experiments demonstrated that the expression of miR-216a-5p was upregulated in RCC (P<0.05) and miR-216a-5p mimics promoted cellular proliferation, viability and motility, and suppressed apoptosis. Conversely, miR-216a-5p inhibitor suppressed cellular proliferation, viability, motility and induced apoptosis. Based on these findings, it was concluded that miR-216a-5p may function as an oncogene in RCC. MiR-216a-5p target genes need to be explored and the potential of miR-216a-5p to be used as a diagnostic or a prognostic biomarker for RCC needs to be validated by future research.